BridgeBio Oncology Therapeutics, Inc(BBOT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBOT BridgeBio Oncology Therapeutics, Inc

交易中 08-25 12:43:09 EDT

9.24

+0.10

+1.04%

最高9.47	最低9.22	成交量4.65万
今开9.24	昨收9.14	日振幅2.74%
总市值7.39亿	流通市值3.30亿	总股本7,999万
成交额43.42万	换手率0.13%	流通股本3,575万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":9.235,"timestamp":1787676186822,"preClose":9.14,"halted":0,"volume":46524,"delay":0,"changeRate":0.010393873085339043,"floatShares":35752400,"shares":79988687,"eps":-5.843879,"marketStatus":"交易中","change":0.095,"latestTime":"08-25 12:43:09 EDT","open":9.24,"high":9.47,"low":9.22,"amount":434168.620932,"amplitude":0.027352,"askPrice":9.25,"askSize":12,"bidPrice":9.22,"bidSize":433,"shortable":3,"etf":0,"ttmEps":-5.843879,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":9.14,"postHourTrading":{"tag":"盘后","latestPrice":9.25,"preClose":9.14,"latestTime":"19:30 EDT","volume":7478,"amount":68439.12,"timestamp":1787614207210,"change":0.11,"changeRate":0.012035,"amplitude":0.012035},"volumeRatio":0.296999},"requestUrl":"/m/hq/s/BBOT","defaultTab":"news","newsList":[{"id":"1177819577","title":"摩根大通首予BridgeBio Oncology Therapeutics增持评级，目标价27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177819577","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177819577?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:38","pubTimestamp":1783510691,"startTime":"0","endTime":"0","summary":"摩根大通发布研究报告，首次将BridgeBio Oncology Therapeutics, Inc纳入覆盖范围，并给予其“增持”评级。该投行为该股设定了27美元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197660362","title":"BridgeBio Oncology Therapeutics公布2026年第一季度财报及公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1197660362","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197660362?lang=zh_cn&edition=full","pubTime":"2026-05-13 06:09","pubTimestamp":1778623778,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc. 发布了其2026年第一季度的财务业绩，并同步更新了公司运营的最新进展。根据报告，公司目前的现金储备预计足以支持其运营持续至2028年。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194150244","title":"BridgeBio子公司Bbot获美国FDA快速通道资格 Bbo-11818用于治疗晚期KRAS突变胰腺导管腺癌成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1194150244","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194150244?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715708,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc（简称Bbot）宣布，其针对晚期KRAS突变胰腺导管腺癌成人患者的创新疗法Bbo-11818，已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一认定将加速该候选药物的研发和审评进程，为存在迫切未满足医疗需求的患者群体带来新的治疗希望。\n胰腺导管腺癌作为最常见的胰腺癌类型，其KRAS突变亚型长期以来缺乏有效靶向治疗方案。快速通道资格的获得，不仅体现了Bbo-11818在早期研究中展现出的治疗潜力，也意味着该药物在后续临床试验中可获得与FDA更频繁的沟通交流机会，有望更快推进至上市申请阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181220084","title":"BridgeBio Oncology Therapeutics, Inc：更新版一期临床数据预计将于2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1181220084","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181220084?lang=zh_cn&edition=full","pubTime":"2026-04-21 04:08","pubTimestamp":1776715701,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics, Inc 近日透露，其备受关注的一期临床试验更新数据预计在2026年下半年揭晓。这一时间表的公布，为关注该公司研发进展的投资者与行业观察者提供了明确预期。\n此次数据更新对于评估相关候选药物的安全性与初步疗效具有关键意义。公司研发管线的最新动态，或将影响其未来的临床开发策略与市场定位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612424818","title":"Bridgebio Oncology Therapeutics, Inc.盘中异动 下午盘股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612424818","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2612424818?lang=zh_cn&edition=full","pubTime":"2026-02-19 03:45","pubTimestamp":1771443943,"startTime":"0","endTime":"0","summary":"北京时间2026年02月19日03时45分，Bridgebio Oncology Therapeutics, Inc.股票出现异动，股价大幅拉升5.11%。Bridgebio Oncology Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Bridgebio Oncology Therapeutics, Inc.公司简介：BridgeBio Oncology Therapeutics Inc，前身为BridgeBio Oncology Therapeutics，是一家临床阶段生物技术公司，旨在改变由两种经常发生突变的致癌基因RAS和PI3Ka驱动的癌症的患者生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219034544a7080f77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219034544a7080f77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","LENZ","BBOT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bbotx.com;investors.bbotx.com","stockEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.092},{"period":"6month","weight":-0.1126},{"period":"1year","weight":0.0339},{"period":"ytd","weight":-0.27}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0172},{"period":"6month","weight":0.1014},{"period":"1year","weight":0.1831},{"period":"ytd","weight":0.1196}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Oncology Therapeutics, Inc.于2021年6月15日作为开曼群岛豁免公司注册成立。自2025年8月12日起，该公司完成了先前宣布的业务合并，合并后的公司注册地位于特拉华州。BBOT是一家临床阶段的生物技术公司，其使命是在RAS和PI3K α这两种最常发生突变的癌基因的驱动下改变癌症患者的生活。","exchange":"NASDAQ","name":"BridgeBio Oncology Therapeutics, Inc","nameEN":"BridgeBio Oncology Therapeutics, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Oncology Therapeutics, Inc(BBOT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Oncology Therapeutics, Inc(BBOT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Oncology Therapeutics, Inc,BBOT,BridgeBio Oncology Therapeutics, Inc股票,BridgeBio Oncology Therapeutics, Inc股票老虎,BridgeBio Oncology Therapeutics, Inc股票老虎国际,BridgeBio Oncology Therapeutics, Inc行情,BridgeBio Oncology Therapeutics, Inc股票行情,BridgeBio Oncology Therapeutics, Inc股价,BridgeBio Oncology Therapeutics, Inc股市,BridgeBio Oncology Therapeutics, Inc股票价格,BridgeBio Oncology Therapeutics, Inc股票交易,BridgeBio Oncology Therapeutics, Inc股票购买,BridgeBio Oncology Therapeutics, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Oncology Therapeutics, Inc(BBOT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Oncology Therapeutics, Inc(BBOT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}